Bulley, Margaret

From: labclientservice

Sent: Tuesday, April 30, 2019 10:20 AM

To: GME PC; Ortolf, Barbara; Salvatore, Alicia; Regional Physicians Group Directors of

Operations; Regional Physician Group Physicians; Regional Physician Group Practice Managers; CPUP DOO's; CPUP Managers; Allen, Kathleen; Grier, Kathy; Theurkauf, Linda; Viola, Kathy; Redmond, Cassandra I; Khemraj, Darci; Major, Katherine; CPUP Business

Administrators

Cc: Fogt, Franz; Atweh, Mahmoud (Michael); Brooks, John; Hunt, William; Gualtieri, Roseann;

Murphy, Alice M; Elenitoba-Johnson, Kojo; Morrissette, Jennifer; Rosenbaum, Jason; Roth, Jacquelyn J; Lieberman, David B (Pathology); Milano, Joe; Nachamkin, Irving; Mincarelli, Deborah; Bulley, Margaret; Danoski, Daniel; McLaughlin, Cara; Vespasiani,

Lynn; Long, Jeff; Acker, David; Agront, Sarita; Bahar, Wael Y; Mcaleer, Diane S;

Macchione, Gerald; Kim, Sharon; Metheny, Robert

Subject: PENN MEDICINE - New Penn Precision Panel: Center for Personalized Diagnostics (CPD)

Attachments: CPD Notification New Penn Precision Panel.docx



University of Pennsylvania Health System

To: UPHS Physicians and Staff

From: The Division of Precision and Computational Diagnostics (PCD)

Kojo Elenitoba-Johnson, M.D., Director, Center for Personalized Diagnostics Jennifer Morrissette, Ph.D., Clinical Director, Center for Personalized Diagnostics

Jason Rosenbaum, M.D., Assistant Professor of Clinical Pathology and Laboratory Medicine Jacquelyn Roth, Ph.D., Assistant Professor of Clinical Pathology and Laboratory Medicine

Date: May 1, 2019

Re: New Penn Precision Panel: Center for Personalized Diagnostics (CPD)

The Center for Personalized Diagnostics (CPD) offers assays designed to detect genomic variants in oncology samples. The CPD is pleased to announce a new **Penn Precision Panel (PPP2.0)**, detecting single nucleotide variants and small (≤30 base pair) insertions and deletions with diagnostic, prognostic and therapeutic utility in various solid tumors. PPP2.0 will replace the current 20 gene PPP panel on **May 1, 2019**. The updated panel includes 39 additional genes and expanded sample acceptability criteria; all genes/regions from PPP1.0 are included on PPP2.0. Specimens submitted for our **Solid Tumor Panel** can be reflexed to the **Penn Precision Panel** if the specimen does not meet the input requirements for the full panel (see ordering information below).

This assay will detect critical hotspots in the following 59 genes (* indicates full coding sequence coverage):

ABL1	EGFR	GNA11	MAP2K1	RET
AKT1	EIF1AX	GNAQ	MET	ROS1
ALK	ERBB2	GNAS	MPL	STK11
APC	ERBB4	HNF1A	MSH6	SMAD4
ATM	ESR1	HRAS	NOTCH1	SMARCB1
BRAF	EZH2	IDH1	NPM1	SMO
CDH1	FBXW7	IDH2	NRAS	SRC
CDKN2A	FGFR1	JAK2	PDGFRA	TP53*

CSF1R	FGFR2	JAK3	PIK3CA	TSC1
CTNNB1	FGFR3	KDR	PTEN	TSHR
DDR2	FLT3	KIT	PTPN11	VHL
DNMT3A	FOXL2	KRAS	RB1	

This assay will not detect fusion transcripts or copy number alterations, and may not detect large (>30 base pair) insertions or deletions. For more details on assay design, please contact the CPD (see below).

SAMPLE REQUIREMENTS: This assay can be used for testing on formalin-fixed paraffin embedded (FFPE) tissues (minimum 10% tumor), tissue or fluid in PreservCyt, blood and bone marrow. This assay is agnostic regarding the tissue-type of the diagnosis.

TURNAROUND TIME: 14-21 business days after reflex from Solid Tumor Panel.

ORDERING INFORMATION: in PennChart, select "Anatomic Pathology Consult (APCONS)". Choose from "Special Studies" drop down menu (Solid Tumor Panel with reflex to PPP).

For additional information and questions: Call the Center for Personalized Diagnostics (215-615-3966) weekdays during regular business hours or visit our website: http://pennmedicine.sitecoreauthoring.uphs.upenn.edu/departments-and-centers/center-for-personalized-diagnostics/gene-panels